Indiana
Indianapolis, Indiana, 46202, United States
NCT Number: NCT02912728
The primary objective of this study is to compare the efficacy and safety of CGM alone and CGM combined with a family behavioral intervention with a control group using home blood glucose monitoring (BGM) alone.
Looking for future studies?
Notify Me2 year–7 year
All sexes
Interventional
Not applicable
Indianapolis, Indiana, 46202, United States
Although prior studies have not demonstrated that continuous glucose monitoring (CGM) use results in improved glycemic control in children <8 years of age, many of the barriers to CGM efficacy in this age group may have been due to problems in the wearability and accuracy of prior generation devices, as well as to the setting of glycemic targets aimed primarily at preventing hypoglycemia at all costs. There may also be behavioral barriers to consistent and effective CGM use in this age range. The goal of this study is to assess the impact of CGM alone and CGM combined with a family behavioral intervention focused on supporting CGM use on glycemic control in very young children with T1D compared with usual care without CGM.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
Other names: FBI
use of CGM alone to assess CGM adherence
Time frame: Up to 26 weeks
The primary outcome will be three 2 group comparisons of the change from baseline in the percentage of sensor values in the target range (70-180 mg/dL), in an ANCOVA model adjusted for the baseline value and factors used to stratify randomization with clinical site as a random effect. Seven days of sensor glucose values during the week prior to the 6, 13, 19 and 26 week clinic visits will be used in analysis for the CGM groups to match up with the blinded CGM placed at each visit in the control group. The CGM data will be pooled across each visit where CGM data are collected during follow up for the primary analysis.
Time frame: 6 Months
A secondary outcome is to compare HbA1c at 6-months, adjusted for baseline.
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Time frame: 6 Months
Survey containing 5 questions with possible responses 0-5. The raw score is calculated by summing the responses. The raw score ranges from 0-25. A percentage score ranging from 0 to 100 is obtained by multiplying the raw score by 4. A percentage score of 0 represents worst possible, whereas a score of 100 represents best possible quality of life.
Time frame: 6 Months
Survey containing 26 questions with possible responses 0-4. Total score is calculated by taking the mean of the non-missing responses and multiplying by 25 to put on the scale 0-100. A higher score indicates more fear.
Time frame: 6 Months
Survey containing 26 questions with possible responses 0-4. Worry subscale score is calculated by taking the mean of the non-missing responses to questions 11-26 and multiplying by 25 to put on the scale 0-100. A higher score indicates more fear.
Time frame: 6 Months
Survey containing 30 questions with possible responses 0-4. Total score is calculated by taking the mean of the non-missing responses and multiplying by 100 to put on the scale 0-100. A higher total score indicates less of a problem.
Time frame: 6 Months
Survey containing 18 questions with possible responses 0-4. Total score is calculated by reverse scoring each item, then taking the mean of the non-missing responses. The score is then multiplied by 25 to put on the scale 0-100. A higher total score indicates more burden.
Time frame: 6 Months
Survey containing 15 questions with possible responses 0-3. Total score is calculated by taking the mean of the non-missing responses. Then multiply by 100 and divide by 3 to put on the scale 0-100. A higher total score indicates more negative impact.
Time frame: 6 Months
Section 2 of the satisfaction questionnaire contains 8 questions for the CGM groups only with possible responses 0-4. Total score is calculated by taking the mean of the non-missing responses and multiplying by 25 to put on the scale 0-100. A higher total score indicates more satisfaction with the study.
Jaeb Center for Health Research
Other
Strategies to Enhance New CGM Use in Early Childhood: A Randomized Clinical Trial to Assess the Efficacy and Safety of Continuous Glucose Monitoring in Youth < 8 With Type 1 Diabetes
Acronym: SENCE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07696039
Autoimmune Diseases, Diabetes Mellitus
Bergamo, Italy
View Trial DetailsNCT03263494
Autoimmune Diseases, Diabetes Mellitus
Los Angeles, California, United States
View Trial DetailsNCT07090824
Autoimmune Diseases, Diabetes Mellitus
Palo Alto, California, United States
View Trial DetailsNCT05211479
Adolescent, Anxiety Disorders
Yalova, Turkey (Türkiye)
View Trial Details